Sevoflurane-Remifentanil Interaction: Multiple Response Surfaces, Validation of Calibration Stimuli, Validation of the Intraoperative Isobole Concept and Investigating Remifentanil Induced Opioid Tolerance
NCT ID: NCT00522587
Last Updated: 2013-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2008-04-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nitrous Oxide - Sevoflurane-Remifentanil Interaction
NCT01103193
Interaction of Sevoflurane Propofol and Remifentanil in Anesthesia for Laparoscopic Surgery
NCT02457442
Blood Levels of Sevoflurane and Desflurane
NCT03015350
Efficacy and Safety of Remifentanil for Mechanically Ventilated Patients in ICU
NCT05003570
the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation
NCT02635802
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Fixed sevoflurane dose 1
Fixed sevoflurane dose 1
Dose 1 of sevoflurane
2
Fixed sevoflurane dose 2
Fixed sevoflurane dose 2
Dose 2 of sevoflurane
3
Fixed sevoflurane dose 3
Fixed sevoflurane dose 3
Dose 3 of sevoflurane
4
Fixed sevoflurane dose 4
Fixed sevoflurane dose 4
Dose 4 of sevoflurane
5
Fixed sevoflurane dose 5
Fixed sevoflurane dose 5
Dose 5 of sevoflurane
6
Fixed sevoflurane dose 6
Fixed sevoflurane dose 6
Dose 6 of sevoflurane
7
Fixed remifentanil dose 1
Fixed remifentanil dose 1
Dose 1 of remifentanil
8
Fixed remifentanil dose 2
Fixed remifentanil dose 2
Dose 2 of remifentanil
9
Fixed remifentanil dose 3
Fixed remifentanil dose 3
Dose 3 of remifentanil
10
Fixed remifentanil dose 4
Fixed remifentanil dose 4
Dose 4 of remifentanil
11
Fixed remifentanil dose 5
Fixed remifentanil dose 5
Dose 5 of remifentanil
12
Fixed remifentanil dose 6
Fixed remifentanil dose 6
Dose 6 of remifentanil
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fixed sevoflurane dose 1
Dose 1 of sevoflurane
Fixed sevoflurane dose 2
Dose 2 of sevoflurane
Fixed sevoflurane dose 3
Dose 3 of sevoflurane
Fixed sevoflurane dose 4
Dose 4 of sevoflurane
Fixed sevoflurane dose 5
Dose 5 of sevoflurane
Fixed sevoflurane dose 6
Dose 6 of sevoflurane
Fixed remifentanil dose 1
Dose 1 of remifentanil
Fixed remifentanil dose 2
Dose 2 of remifentanil
Fixed remifentanil dose 3
Dose 3 of remifentanil
Fixed remifentanil dose 4
Dose 4 of remifentanil
Fixed remifentanil dose 5
Dose 5 of remifentanil
Fixed remifentanil dose 6
Dose 6 of remifentanil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-60 years
* Scheduled for surgery under general anesthesia
Exclusion Criteria
* Neurological disorder
* Diseases involving the cardiovascular system (hypertension, coronary artery disease, prior acute myocardial infarction (AMI), any valvular and/or muscular disease involving decrease of the ejection fraction, arrhythmias, which are either symptomatic or require continuous medication/pacemaker/automatic implantable cardioverter defibrillator \[AICD\])
* Pulmonary disease including asthma, severe chronic obstructive pulmonary disease (COPD), etc.
* Gastric diseases including reflux, endocrinological diseases
* Recent use of psycho-active medication, including alcohol.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michel Struys, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ghent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Ghent
Ghent, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Website of the University Hospital Ghent
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007/242
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.